Eli Lilly concedes a PhIII flop for abemaciclib as breakout strategy flounders
Just days after a laggard Eli Lilly won its first approval for its CDK4/6 cancer drug abemaciclib, the pharma giant has been forced to concede …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
